Skye Bioscience, Inc. (SKYE)
NASDAQ
Key stats Fiscal year 2025
Income statement
- Net income
- -55,924,814
- Operating income
- -58,163,565
- Earnings per share
- -1.41
Growth and profitability
- Return on equity
- -279.29
- Return on assets
- -197.52
Balance sheet
- Total assets
- 28,313,633
- Total liabilities
- 8,289,458
- Shareholders' equity
- 20,024,175
- Cash and equivalents
- 5,882,498
- Current ratio
- 3.30
Cash flow and ratios
- Operating cash flow
- -43,062,529
- Free cash flow
- -43,068,841
Shareholder returns
- Shares outstanding
- 4,423,469
- Book value per share
- 4.53
Company information
- Headquarters
- San Diego, CA
- Exchange
- NASDAQ
- Fiscal year end
- 12-31
- Industry (SEC)
- Pharmaceutical Preparations
Fiscal year end: · Source: SEC EDGAR
Skye Bioscience, Inc. trades on NASDAQ under the ticker symbol SKYE. This page brings together its price chart, company profile, key financial figures and technical indicators.